Market Synopsis:

Global Automated Immunoassay Analyzers market is valued at USD 10.13 Billion in 2021 and is projected to attain a value of USD 28.15 Billion by 2028 at a CAGR of 14.15% during the forecast period, 2022–2028. The market for automated immunoassay analyzers is expected to develop due to the growing trend toward lab automation and the rising occurrence of infectious disorders. Due to incremental improvements to current items and expanded clinical applications, these products are gaining appeal. As a result of the increased use of automated immunoassay analyzers, demand and adoption rates will rise, propelling the market forward.

Recent automation and integration trends have resulted in the introduction of unique goods to the industry, hence propelling the market forward. They are increasingly being used for drug discovery by a variety of pharmaceutical and biotechnology companies. To obtain access to hospitals and laboratories, industry competitors are competing on the basis of immunoassay system features, throughput, and menu growth.

Increasing Incidence of Chronic and Infectious Diseases

Chronic diseases including diabetes, heart disease, and cancer are on the rise all across the world. Infectious diseases such as SARS-CoV2 (COVID-19), Dengue fever, Hepatitis B, C, HIV, Malaria, Tuberculosis, and others are spreading at an alarming rate. Immunoassay diagnosis has become a critical component of many disorders' diagnosis. Immunoassay technology is improving, resulting in faster results with improved efficacy, detection limits, sensitivity, and cost-effectiveness. The widespread use of fast tests and point-of-care testing for disease diagnosis, as well as drug and alcohol addiction, has propelled the worldwide immunoassay market to new heights.

Design Challenges

The technicians face lots of design challenges associated with the immunoassays such as misinterpretation of results. Also, the dearth of skilled professionals in the clinical diagnostics domain have posed challenges from several decades.

The Automated Immunoassay Analyzers market scope can be tabulated as below:

Market Segmentation:

Global Automated Immunoassay Analyzers market is segmented on the basis of Analyzers, into Biochemistry Analyzers, Immuno-based Analyzers, Hematology Analyzers. Based on Application into Drug Discovery, Geonomics, Others. Based on region, the Automated Immunoassay Analyzers market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

North America to Continue Dominating the Automated Immunoassay Analyzers Market

During the projected period, North America is expected to dominate the worldwide Automated Immunoassay Analyzers market, followed by Europe. Increased adoption of technologically advanced Automated Immunoassay Analyzers products, high healthcare expenditures, advanced healthcare infrastructure, highly developed healthcare systems in the US and Canada, a large number of Automated Immunoassay Analyzers-based R&D projects, and the presence of a large number of leading Automated Immunoassay Analyzers manufacturers in the region, as well as increased demand for genotyping products from pharmaceutical companies and rising government investments, by government bodies, are responsible for the large share of the North American Automated Immunoassay Analyzers market.

Key Players:

Key participants operating in the Automated Immunoassay Analyzers market is: Abbott Diagnostics (US)

The Automated Immunoassay Analyzers market is segmented as follows: